Stocktoria
Dianthus Therapeutics, Inc. /DE/ DNTH
Dianthus Therapeutics, Inc. /DE/ (DNTH) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.0M at a -7973.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-06 | Wedbush | Outperform (main) |
| 2026-04-09 | Wolfe Research | Outperform (init) |
| 2026-03-19 | Wells Fargo | Overweight (init) |
| 2026-03-12 | Wedbush | Outperform (main) |
| 2026-03-10 | Wedbush | Outperform (main) |
| 2026-03-10 | Raymond James | Strong Buy (up) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.713 |
| Retained earnings / assets | -0.634 |
| EBIT / assets | -0.335 |
| Equity / liabilities | 13.15 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 1/9 | 14.17 | — | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | 2/9 | 7.8 | 3 | — |
| CYCN | Cyclerion Therapeutics, Inc. | 1/9 | — | — | — |
| LPCN | Lipocine Inc. | — | — | — | -82.3% |
| BIOE | Bio Essence Corp | 9/9 | — | 14.1 | — |
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
About Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
FAQ
Is DNTH financially healthy?
Dianthus Therapeutics, Inc. /DE/'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DNTH pay a dividend?
No, Dianthus Therapeutics, Inc. /DE/ does not currently pay a dividend.
How profitable is DNTH?
In FY2025, Dianthus Therapeutics, Inc. /DE/ had a net margin of -7973.3% and a return on equity of -32.9%.
What is the analyst price target for DNTH?
The average Wall-Street price target for Dianthus Therapeutics, Inc. /DE/ is $127.67, about 13.6% above the recent price, from 12 analysts (consensus: strong buy).
Is DNTH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Dianthus Therapeutics, Inc. /DE/: a Piotroski F-score of 1/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.